Search Results - "Gaynor, Ellen R."

Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment Selection by Lo, Shelly S, Mumby, Patricia B, Norton, John, Rychlik, Karen, Smerage, Jeffrey, Kash, Joseph, Chew, Helen K, Gaynor, Ellen R, Hayes, Daniel F, Epstein, Andrew, Albain, Kathy S

“…The 21-gene Recurrence Score (RS) assay has been validated to quantify the risk of distant recurrence in tamoxifen-treated patients with lymph node-negative,…”
Get full text

Health Status and Quality of Life in Patients With Early-Stage Hodgkin’s Disease Treated on Southwest Oncology Group Study 9133 by GANZ, Patricia A, MOINPOUR, Carol M, FISHER, Richard I, PAULER, Donna K, KORNBLITH, Alice B, GAYNOR, Ellen R, BALCERZAK, Stanley P, GATTI, Gretchen S, ERBA, Harry P, MCCOY, Sheryl, PRESS, Oliver W

“…We describe the short and intermediate-term quality-of-life (QOL) outcomes in patients treated on a randomized clinical trial in early-stage Hodgkin's disease…”
Get full text

Phase III Randomized Intergroup Trial of Subtotal Lymphoid Irradiation Versus Doxorubicin, Vinblastine, and Subtotal Lymphoid Irradiation for Stage IA to IIA Hodgkin’s Disease by PRESS, Oliver W, LEBLANC, Michael, LICHTER, Allen S, GROGAN, Thomas M, UNGER, Joseph M, WASSERMAN, Todd H, GAYNOR, Ellen R, PETERSON, Bruce A, MILLER, Thomas P, FISHER, Richard I

“…The management of early-stage Hodgkin's disease in the United States is controversial. To evaluate whether staging laparotomy could be safely avoided in…”
Get full text

Dose-Intense Chemotherapy Every 2 Weeks With Dose-Intense Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone May Improve Survival in Intermediate- and High-Grade Lymphoma: A Phase II Study of the Southwest Oncology Group (SWOG 9349) by BLAYNEY, Douglas W, LEBLANC, Michael L, GROGAN, Thomas, GAYNOR, Ellen R, CHAPMAN, Robert A, SPIRIDONIDIS, C. Harris, TAYLOR, Sarah A, BEARMAN, Scott I, MILLER, Thomas P, FISHER, Richard I

“…To test the hypothesis that therapy of intermediate- and high-grade (excluding Burkitt lymphoblastic) lymphoma with cyclophosphamide, doxorubicin, vincristine,…”
Get full text

Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy by Korpics, Mark C., Block, Alec M., Martin, Brendan, Hentz, Courtney, Gaynor, Ellen R., Henry, Elizabeth, Harkenrider, Matthew M., Solanki, Abhishek A.

“…BACKGROUND The current study was conducted to compare the overall survival (OS) of concurrent chemoradiotherapy (CCRT) versus radiotherapy (RT) alone in…”
Get full text

A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911 by Press, Oliver W., Unger, Joseph M., Braziel, Rita M., Maloney, David G., Miller, Thomas P., LeBlanc, Michael, Gaynor, Ellen R., Rivkin, Saul E., Fisher, Richard I.

“…Advanced follicular lymphoma is incurable with conventional chemotherapy and radiotherapy. The Southwest Oncology Group (SWOG) conducted a phase 2 trial…”
Get full text

Infusional CHOP Chemotherapy (CVAD) With or Without Chemosensitizers Offers No Advantage Over Standard CHOP Therapy in the Treatment of Lymphoma: A Southwest Oncology Group Study by GAYNOR, Ellen R, UNGER, Joseph M, MILLER, Thomas P, GROGAN, Thomas M, WHITE, Leonard A, MILLS, Glenn M, BALCERZAK, Stanley P, VARTERASIAN, Mary, LEBLANC, Michael, FISHER, Richard I

“…Two phase II studies were conducted to evaluate infusional cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy, termed the CVAD regimen,…”
Get full text

Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin’s disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208 by Moinpour, Carol M., Unger, Joseph M., Ganz, Patricia A., Kornblith, Alice B., Gaynor, Ellen R., Bowers, Mindy Ann, Gatti, Gretchen S., Kaminski, Mark S., Erba, Harry Paul, Wang, Ting, Yoon, Jihye, Press, Oliver W., Fisher, Richard I.

“…Purpose We describe 7 years of follow-up for the energy/vitality outcome in early-stage Hodgkin’s disease patients treated on a randomized clinical trial that…”
Get full text

Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma by Fisher, Richard I, Gaynor, Ellen R, Dahlberg, Steve, Oken, Martin M, Grogan, Thomas M, Mize, Evonne M, Glick, John H, Coltman, Charles A, Miller, Thomas P

“…The development of curative combination chemotherapy for patients with advanced stages of aggressive non-Hodgkin's lymphoma has been one of the major successes…”
Get full text

Interferon Alfa Consolidation After Intensive Chemotherapy Does Not Prolong the Progression-Free Survival of Patients With Low-Grade Non-Hodgkin’s Lymphoma: Results of the Southwest Oncology Group Randomized Phase III Study 8809 by Fisher, Richard I., Dana, Bruce W., LeBlanc, Michael, Kjeldsberg, Carl, Forman, Jeffrey D., Unger, Joseph M., Balcerzak, Stanley P., Gaynor, Ellen R., Roy, Vivek, Miller, Thomas

“…PURPOSE: S8809 is a randomized phase III trial determining whether intensive cytoreductive treatment, followed by interferon consolidation at the time of…”
Get full text

Octreotide for Refractory Diarrhea Associated with Capecitabine by Tanvetyanon, Tawee, Gaynor, Ellen R

“…Objective: To describe the effect of low-dose subcutaneous octreotide on refractory diarrhea associated with capecitabine. Case Summary: A 67-year-old white…”
Get full text

Trends in utilization of novel oral therapeutic agents for men with metastatic castrate-resistant prostate cancer within the United States Veteran’s Affairs Health System by Henry, Elizabeth, Silva, Abigail, Tarlov, Elizabeth, Gaynor, Ellen R.

“…Abstract only 220 Background: Therapeutic options for men with metastatic castrate resistant prostate cancer (mCRPC) have expanded significantly over the past…”
Get full text

A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study by Whitehead, Robert P, Benedetti, Jacqueline K, Abbruzzese, James L, Ardalan, Bach, Williamson, Stephen, Gaynor, Ellen R, Balcerzak, Stanley P, Macdonald, John S

“…The purpose of this phase II multi-institutional study was to define the efficacy and toxicity of infusional 5-FU in combination with PALA and leucovorin in…”
Get full text

Daily Subcutaneous Ultra-Low-Dose Interleukin 2 with Daily Low-Dose Interferon-α in Patients with Advanced Renal Cell Carcinoma by CLARK, J. I, GAYNOR, E. R, MARTONE, B, BUDDS, S. C, MANJUNATH, R, FLANIGAN, R. C, WATERS, W. B, SOSMAN, J. A

“…A limited institution Phase II pilot study was performed using a very low-dose combination of daily s.c. interleukin (IL)-2 with IFN-α-2b in patients with…”
Get full text

Effect of concurrent chemotherapy on overall survival in elderly bladder cancer patients undergoing radiotherapy: A population-based analysis by Solanki, Abhishek Ashok, Block, Alec, Henry, Elizabeth, Gaynor, Ellen R., Harkenrider, Matthew M., Welsh, James, Small, William

“…Abstract only…”
Get full text

Association of treatment facility case volume with survival in patients undergoing radiotherapy/chemoradiotherapy for muscle-invasive bladder cancer: An analysis of the National Cancer Database by Bajaj, Amishi, Block, Alec, Martin, Brendan, Korpics, Mark, Hentz, Courtney, Blackwell, Robert H, Gaynor, Ellen R., Henry, Elizabeth, Gupta, Gopal Nand, Harkenrider, Matthew M., Solanki, Abhishek Ashok

“…Abstract only 295 Background: Excellent outcomes with bladder-preserving trimodality therapy have been demonstrated at centers with expertise and high-volume…”
Get full text

Abstract P6-08-42: Association of metabolic syndrome, its components and multigene assays for recurrence risk by Mai, Hanh P, Kliethermes, Stephanie, Jain, Shikha, Lo, Shelly S, Gaynor, Ellen R, Albain, Kathy S, Robinson, Patricia

“…Abstract Background: There is an association of metabolic syndrome (MS) and its constituents (obesity; diabetes mellitus, DM; hypertension, HTN;…”
Get full text

Comparison of the intermediate risk 21-gene recurrence score (RS) with the 70-gene signature (GS) as a continuous variable, Magee equations, and Adjuvant! Online (AOL) by Mai, Hanh P., Kliethermes, Stephanie, McCroskey, Zulfia, Ersahin, Cagatay, Gaynor, Ellen R., Robinson, Patricia A., Albain, Kathy S., Lo, Shelly S.

“…Abstract only 47 Background: Multigene assays and risk-prediction models are used to provide prognostic information in the management of patients with estrogen…”
Get full text

Abstract S4-03: Identification of a notch-driven breast cancer stem cell gene signature for anti-notch therapy in an ER+ presurgical window model by Albain, Kathy S, Zlobin, Andrei Y, Covington, Kyle R, Gallahger, Brian T, Hilsenbeck, Susan G, Czerlanis, Cheryl M, Lo, Shelly, Robinson, Patricia A, Gaynor, Ellen R, Godellas, Constantine, Bova, Davide, Czaplicki, Kathy, Busby, Barbara, Stiff, Patrick J, Fuqua, Suzanne AW, Miele, Lucio, Osipo, Clodia

“…Abstract Background: Resistance to endocrine therapy (ET; tamoxifen or aromatase inhibitors, AI) for ER+ breast cancer is a major cause of mortality and new…”
Get full text

Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors by Sparano, J A, Fisher, R I, Weiss, G R, Margolin, K, Aronson, F R, Hawkins, M J, Atkins, M B, Dutcher, J P, Gaynor, E R, Boldt, D H

“…Treatment with interleukin-2 (IL-2) used alone or in combination with lymphokine-activated killer (LAK) cells is known to be an active therapy for patients…”
Get more information